All Photos(1)
2-Fluoro-N′-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide, 3-Fluoro-N′-(2-fluorophenyl)sulfonyl-5-(2-pyridyl)benzohydrazide, WM 1119, WM1119
C18H13F2N3O3S
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
FC1=CC(C2=NC=CC=C2)=CC(C(NNS(C3=CC=CC=C3F)(=O)=O)=O)=C1
Biochem/physiol Actions
WM-1119 is a potent and selective, acetyl coenzyme A (Acetyl-CoA)-competitive inhibitor against MYST family histone acetyltransferases KAT6A and KAT6B (KAT6B Kd = 2.1 nM by SPR, IC50 = 37 nM by activity assay; KAT7/5 Kd = 0.53/2.2 μM; no affinity toward 159 diverse biological targets). WM-1119 induces MEF G1 cell cycle arrest (1-10 μM), inhibits EMRK1184 lymphoma growth in cultures (IC50 = 250 nM) and in mice in vivo (50 mg/kg 3x or 4x i.p. per day).
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Nature, 560(7717), 253-257 (2018-08-03)
Acetylation of histones by lysine acetyltransferases (KATs) is essential for chromatin organization and function1. Among the genes coding for the MYST family of KATs (KAT5-KAT8) are the oncogenes KAT6A (also known as MOZ) and KAT6B (also known as MORF and
Journal of medicinal chemistry, 63(9), 4655-4684 (2020-03-03)
A high-throughput screen designed to discover new inhibitors of histone acetyltransferase KAT6A uncovered CTX-0124143 (1), a unique aryl acylsulfonohydrazide with an IC50 of 1.0 μM. Using this acylsulfonohydrazide as a template, we herein disclose the results of our extensive structure-activity
Nature, 577(7789), 266-270 (2019-12-13)
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulation that results in a block in differentiation and increased malignant self-renewal. Various epigenetic therapies aimed at reversing these hallmarks of AML have progressed into clinical trials, but most
Nature communications, 11(1), 3455-3455 (2020-07-15)
CRISPR-based genetic screening has revolutionized cancer drug target discovery, yet reliable, multiplex gene editing to reveal synergies between gene targets remains a major challenge. Here, we present a simple and robust CRISPR-Cas12a-based approach for combinatorial genetic screening in cancer cells.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service